We've prepared an analysis of the top 10 most expensive drugs in the US compared with Germany, in th...
Read moreWe summarise key pharmaceutical, pricing and market access insights that are worth reading about thi...
Read moreOur client was seeking NICE approval for their ultra-orphan drug in an indication that was not well ...
Read moreOur client was struggling to understand the value of their product (a single-use treatment for an ul...
Read moreWe summarise the ISPOR Europe 2022 conference including plenary sessions on HTA, patient-centered re...
Read moreWe compare the rates of positive reimbursement decisions in England and EU4 for orphan drugs approve...
Read moreThis updated bill contains some similar measures to those proposed in March as well as some addition...
Read moreUnder ODAP, a protocol is drawn up “with criteria for starting, stopping and effect of a medicine....
Read moreEUCOPE notes that “while these proposals don’t necessarily represent the final options included ...
Read moreThe paper examines potential reforms to current policies and practices related to orphan drug develo...
Read more